{"id":81613,"date":"2026-06-11T15:46:40","date_gmt":"2026-06-11T15:46:40","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/81613\/"},"modified":"2026-06-11T15:46:40","modified_gmt":"2026-06-11T15:46:40","slug":"lilly-pledges-500m-to-south-korea-biopharma-industry","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/81613\/","title":{"rendered":"Lilly pledges $500M to South Korea biopharma industry"},"content":{"rendered":"<p>Less than a week after Roche pledged a hefty investment in the South Korean biopharma industry, Eli Lilly is following suit with a $500 million, five-year pact of its own.<\/p>\n<p>Like Roche, Lilly has signed a memorandum of understanding with the South Korean government, a company spokesperson confirmed to Fierce Biotech. Further details of Lilly\u2019s pledge are detailed in a release issued by the South Korean Ministry of Health and Welfare, which was shared with Fierce.<\/p>\n<p>Lilly\u2019s investment is meant to attract clinical trials to South Korea, while also powering new innovation through the opening of an incubator as part of the <a href=\"https:\/\/gatewaylabs.lilly.com\/\" rel=\"nofollow noopener\" target=\"_blank\">Lilly Gateway Labs<\/a> network, according to the release.<\/p>\n<p>The new Gateway Lab will be built in collaboration with Korean manufacturing giant Samsung Biologics and is set to house up to 30 companies, according to a <a href=\"https:\/\/www.prnewswire.com\/news-releases\/samsung-biologics-announces-collaboration-with-lilly-to-establish-new-gateway-labs-site-in-korea-302709355.html\" rel=\"nofollow noopener\" target=\"_blank\">release<\/a> from Samsung.<\/p>\n<p>\u201cThis agreement will serve as a meaningful opportunity to strengthen the innovation capacity of Korea\u2019s pharmaceutical and biopharma industry, while accelerating innovative drug development by promising domestic companies and enhancing their global competitiveness,\u201d Jeong Eun-kyeong, M.D., Ph.D., South Korea\u2019s minister of health and welfare, said in the government release.<\/p>\n<p>Investing in South Korea\u2019s burgeoning bio landscape fits neatly with the Indianapolis drugmaker\u2019s plan to use its weight loss windfall to become a <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/weight-loss-windfall-lilly-looks-become-backbone-global-innovation\" rel=\"nofollow noopener\" target=\"_blank\">hub of global innovation<\/a>, which multiple Lilly leaders have recently outlined to Fierce. Other parts of this endeavor include a <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/lilly-debuts-nvidia-supercomputer-fanfare-and-focus-escaping-traditional-pharma-lifecycle\" rel=\"nofollow noopener\" target=\"_blank\">supercomputer from Nvidia<\/a> and dedicated <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/eli-lilly-and-andreessen-horowitz-link-500m-biotech-venture-fund\" rel=\"nofollow noopener\" target=\"_blank\">venture funds<\/a>.<\/p>\n<p>When forging its similar $484 million pact with South Korea, Roche <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/roche-pumps-480-million-south-korea-biopharma-industry\" rel=\"nofollow noopener\" target=\"_blank\">described<\/a> a goal of building \u201can ecosystem for global clinical trials\u201d and fueling enhanced R&amp;D capabilities.<\/p>\n<p>Lilly has previously sought biotech innovation from South Korea, <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/lilly-strengthens-rna-pipeline-13b-biobucks-hearing-loss-pact\" rel=\"nofollow noopener\" target=\"_blank\">teaming up<\/a> with RNA editing outfit Rznomics last year to co-develop a hearing loss therapy in a deal that could reach $1.3 billion in value.<\/p>\n<p>Other large pharmas have also turned to the East Asian nation for novel candidates in recent years. Vertex Pharmaceuticals <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/vertex-mines-riches-15-million-orum-licensing-deal\" rel=\"nofollow noopener\" target=\"_blank\">inked a small deal<\/a> with Orum in July 2024 for tech to help with new gene editing therapies, while GSK <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/gsks-pens-25b-pact-use-abl-bios-tech-bypass-blood-brain-barrier\" rel=\"nofollow noopener\" target=\"_blank\">garnered<\/a> a brain-penetrating platform from ABL Bio and Boehringer Ingelheim <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/boehringer-ingelheim-digs-adcs-offering-nearly-1b-license-cancer-prospect-koreas-aimedbio\" rel=\"nofollow noopener\" target=\"_blank\">licensed<\/a> an antibody-drug conjugate from AimedBio.<\/p>\n<p>Boehringer sees South Korea as a \u201cstrategic innovation hub\u201d in Asia, a spokesperson for the German pharma told Fierce, and is currently running 50 global trials there spanning all stages of development.<\/p>\n<p>In 2024, Boehringer <a href=\"https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=27113\" rel=\"nofollow noopener\" target=\"_blank\">established<\/a> a Korean Business Development and Licensing function to \u201cdeepen open innovation partnerships with Korean biotech companies,\u201d the spokesperson said.<\/p>\n<p>Over in the venture capital world, Flagship Pioneering made a <a href=\"https:\/\/www.prnewswire.com\/apac\/news-releases\/flagship-pioneering-expands-into-asia-pacific-region-with-regional-hub-in-singapore-301980173.html\" rel=\"nofollow noopener\" target=\"_blank\">concerted effort<\/a> to expand into the Asia-Pacific region in November 2023, hiring McKinsey vet Andr\u00e9 Andonian to lead the effort. Andonian <a href=\"https:\/\/www.mk.co.kr\/en\/it\/11982121\" rel=\"nofollow noopener\" target=\"_blank\">recently told<\/a> the Maeil Business Newspaper that South Korea is a priority for Flagship\u2019s strategy.<\/p>\n<p>The firm\u2014which is responsible for a plethora of biotech startups, including Moderna\u2014brought BG Rhee, Ph.D., on board as special advisor in South Korea several months ago to <a href=\"https:\/\/www.linkedin.com\/posts\/flagship-pioneering_welcome-bg-rhee-as-special-advisor-to-flagship-activity-7383969938366947328-MbJ5?utm_source=share&amp;utm_medium=member_desktop&amp;rcm=ACoAABfVmh8Bnm5MDKK1JHb5HeyE6iRkYye_L6U\" rel=\"nofollow noopener\" target=\"_blank\">further advance<\/a> its presence in the country.<\/p>\n","protected":false},"excerpt":{"rendered":"Less than a week after Roche pledged a hefty investment in the South Korean biopharma industry, Eli Lilly&hellip;\n","protected":false},"author":2,"featured_media":81614,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[1115,1288,41952,3772,216,9275,41963,251,134,1220],"class_list":["post-81613","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-biotech","tag-clinical-trials","tag-cro","tag-deals","tag-eli-lilly","tag-fierce-biotech-homepage","tag-overseas-clinical-trials","tag-rd","tag-roche","tag-south-korea"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116732256744666757","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/81613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=81613"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/81613\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/81614"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=81613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=81613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=81613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}